Histrelin (Supprelin LA/Vantas) Research Profile — FDA-Approved GnRH Agonist Subdermal Implant 2026

# Histrelin (Supprelin LA/Vantas) Research Profile — FDA-Approved GnRH Agonist Subdermal Implant 2026

> Research Use Only (RUO) Disclaimer: This article is for educational and scientific research purposes only. Histrelin (Supprelin LA, Vantas) is an FDA-approved prescription medication. All clinical use must be under the supervision of a licensed healthcare provider. This content does not constitute medical advice.

Overview

Histrelin is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) — the hypothalamic decapeptide that orchestrates the reproductive axis. Delivered as a unique 12-month subdermal hydrogel implant, histrelin occupies a singular position in both clinical endocrinology and research pharmacology: it provides the most sustained continuous GnRH agonism of any commercially available formulation, making it a powerful tool for studying hypothalamic-pituitary-gonadal (HPG) axis dynamics over extended timeframes.

The FDA has approved two histrelin implant products: Supprelin LA (2007) for central precocious puberty (CPP) in children, and Vantas (2004) for palliative treatment of advanced prostate cancer. Both products use the same 50 mg histrelin-loaded Hydron polymer implant, releasing approximately 65 mcg/day over 12 months.

---

Molecular Structure and Biochemistry

Histrelin is a GnRH decapeptide (technically a nonapeptide with a C-terminal amide) with a critical amino acid substitution at position 6: glycine is replaced by a histidine-imidazolyl derivative, introducing a bulky hydrophobic group that dramatically increases receptor binding affinity and resistance to enzymatic degradation compared to native GnRH.

Molecular formula: C66H86N18O12 (acetate salt)

Molecular weight: 1443.7 Da (free base)

This position-6 substitution gives histrelin its characteristic pharmacological profile:

• •50-200x greater GnRHR binding affinity than native GnRH
• •Prolonged receptor occupancy resistant to endopeptidase cleavage
• •Sustained agonist-induced desensitization — the pharmacological mechanism underlying its clinical utility

---

Mechanism of Action: GnRHR Desensitization and HPG Suppression

Understanding histrelin requires understanding the pulsatile nature of the hypothalamic-pituitary axis. Under physiological conditions, the hypothalamus releases GnRH in discrete pulses every 60-120 minutes. These pulses are essential: the pituitary gonadotroph cells require pulsatile GnRH stimulation to maintain LH and FSH secretion. Continuous, non-pulsatile GnRH exposure paradoxically shuts the system down.

Phase 1: Initial Agonist Flare (Days 1-10)

Upon implant insertion, histrelin occupies GnRH receptors (GnRHR/GNRHR) on pituitary gonadotrophs, triggering an initial "flare" response:

• •Surge in LH and FSH secretion
• •Transient rise in testosterone (men) or estradiol (women/children)
• •Clinically significant: in prostate cancer, this initial flare can transiently worsen symptoms (bone pain, urinary obstruction) before suppression occurs

Phase 2: Receptor Downregulation and Desensitization (Weeks 2-4)

Sustained GnRHR occupancy activates several molecular dampening mechanisms:

1. Receptor internalization — GnRHR-histrelin complexes are endocytosed, reducing surface receptor density

2. Post-receptor uncoupling — G-protein (Gq/11) coupling efficiency decreases

3. Gonadotroph gene suppression — LH-beta and FSH-beta subunit transcription is downregulated

The net effect: pituitary becomes refractory to further GnRH-class stimulation.

Phase 3: Sustained Castrate Suppression (Month 1 onward)

By 4-8 weeks post-implant, most patients achieve medical castration levels:

• •Testosterone: 50 ng/dL or less (often 20 ng/dL or less) in men
• •Estradiol: prepubertal levels (less than 20 pg/mL) in children with CPP
• •LH and FSH: suppressed below prepubertal thresholds

This state is maintained for the full 12-month implant duration, with the continuous 65 mcg/day release rate sustaining receptor saturation without pulsatile recovery windows.

---

FDA-Approved Indications

Supprelin LA — Central Precocious Puberty (CPP)

Approved: May 2007

Indication: Treatment of CPP in children (onset of secondary sexual characteristics before age 8 in girls, age 9 in boys)

CPP results from premature activation of the HPG axis — pathological early GnRH pulsatility that triggers gonadotropin release and gonadarche years ahead of schedule. The clinical consequences are significant: rapid bone age advancement, compromised adult height potential, and psychosocial stress.

Phase 3 trial evidence:

• •The pivotal Supprelin LA trial enrolled 47 children (2-9 years old) with confirmed CPP
• •By month 1: 100% achieved estradiol suppression to prepubertal levels
• •At month 12: 94% maintained suppression (LH peak less than 4 IU/L after leuprolide stimulation test)
• •Bone age advancement rate slowed from 1.97 years/year (pre-treatment) to 0.87 years/year (on-treatment)
• •Mean predicted adult height increased by 2.1 cm vs pre-treatment baseline
• •Implant site reactions were the most common adverse events (bruising, scarring); no systemic hypersensitivity events

Reversibility: Within 3-12 months of implant removal, GnRH pulsatility resumes, LH/FSH rise, and pubertal progression recommences — a feature that makes histrelin implants preferable to permanent interventions and valuable as a reversibility model in HPG axis research.

Vantas — Advanced Prostate Cancer (ADT)

Approved: October 2004

Indication: Palliative treatment of advanced prostate cancer

Androgen deprivation therapy (ADT) is the cornerstone of systemic treatment for hormone-sensitive prostate cancer. By eliminating testicular testosterone production, histrelin deprives prostate cancer cells of their primary growth driver.

Key clinical data:

• •Phase 3 trial: 138 patients with advanced prostate cancer
• •PSA normalization (4 ng/mL or less) achieved in 77% of patients by month 3
• •95% of patients maintained testosterone at or below 50 ng/dL through month 12
• •The 12-month single-implant approach improves adherence vs. monthly or quarterly injections — with compliance-sensitive oncology populations, this is clinically and research-practically significant

Castration-Resistant Prostate Cancer (CRPC) Research:

Even after tumors develop castration resistance, continued androgen suppression via histrelin or other GnRH agonists is maintained in most CRPC protocols, as residual adrenal and intratumoral androgen synthesis can still fuel AR-driven progression. Histrelin's 12-month sustained-release model is used in research settings studying the transition from hormone-sensitive to castration-resistant disease states under controlled continuous androgen suppression.

---

The Hydron Implant System: Pharmacokinetics and Drug Delivery Research

Histrelin's 12-month subdermal implant represents one of the most sophisticated sustained-release pharmaceutical delivery systems in clinical use, and it has become a reference model in drug delivery research.

Implant specifications:

• •Cylindrical hydrogel rod: 3.5 cm x 3.5 mm
• •Polymer matrix: Hydron (poly[2-hydroxyethyl methacrylate], pHEMA) — a hydrophilic polymer that swells in aqueous tissue environments
• •Drug loading: 50 mg histrelin acetate
• •Release rate: approximately 65 mcg/day (zero-order kinetics)
• •Insertion site: inner aspect of the upper arm (subcutaneous)
• •Removal: after 12 months, or at clinical decision

Why Hydron? The pHEMA matrix creates a diffusion-limited release system. As the polymer hydrates post-insertion, histrelin diffuses outward at a rate determined by matrix swelling equilibrium — not burst-release kinetics. This achieves the non-pulsatile continuous delivery that drives GnRHR desensitization without the compliance-critical injection scheduling of leuprolide or triptorelin depot formulations.

Pharmacokinetic parameters:

• •Serum T_max: 12 hours post-insertion
• •Steady-state concentration: approximately 0.25-0.4 ng/mL (maintained throughout 12-month duration)
• •No accumulation or tachyphylaxis of delivery
• •Bioavailability: essentially complete (subcutaneous route)

This kinetic profile — flat, sustained plasma concentration without peaks or troughs — is the pharmacological ideal for maintaining continuous GnRHR saturation, and distinguishes histrelin from injection-based GnRH agonists that require frequent dosing to avoid pulsatile recovery.

---

GnRH Agonist Family Context

Histrelin belongs to the GnRH agonist class alongside several other synthetic analogs, each with distinct structural features and delivery profiles. For researchers selecting a GnRH agonist model system, understanding these distinctions matters:

Histrelin's research advantage: The 12-month continuous implant eliminates dosing frequency as a variable. When studying chronic HPG axis suppression, GnRHR downregulation dynamics, or long-term androgen deprivation effects, histrelin implants provide a pharmacologically cleaner model than requiring repeated injections over the same period.

For acute/pulsatile HPG axis studies, native gonadorelin remains the reference compound. For injectable depot suppression paradigms, leuprolide is the most widely used with the broadest human clinical dataset.

---

Research Applications

1. Hypothalamic-Pituitary-Gonadal (HPG) Axis Studies

The histrelin implant system is a gold-standard tool for inducing controlled, prolonged HPG axis suppression in clinical research. Applications include:

• •Gonadal steroid deprivation models: Studying the effects of sex hormone absence on bone density, muscle metabolism, cognition, and cardiovascular parameters over 12 months with a single intervention
• •LH/FSH dynamics: Quantifying the kinetics of GnRHR downregulation and gonadotropin suppression timecourse
• •Reversibility studies: Characterizing HPG axis recovery after implant removal — the time-course, completeness, and inter-individual variability of axis reactivation

2. GnRHR Desensitization and Receptor Biology

Continuous histrelin exposure creates a defined desensitized GnRHR state reproducible across study subjects. Researchers use this to:

• •Study GnRHR internalization and recycling kinetics in vivo
• •Characterize post-receptor signaling adaptation (beta-arrestin recruitment, MAPK pathway regulation)
• •Test GnRH antagonist challenges against a desensitized receptor background (antagonist sensitivity studies)

3. Pediatric Puberty Timing Research

Supprelin LA provides a reversible, single-intervention method for studying puberty timing mechanisms in humans:

• •Prospective bone age vs. height velocity relationships under controlled hormonal suppression
• •Neurological and cognitive correlates of delayed puberty onset
• •Long-term adult height and fertility outcomes after childhood HPG axis suppression
• •The psychological and quality-of-life impacts of puberty delay

4. Prostate Cancer and CRPC Models

In prostate cancer research settings, histrelin's 12-month implant enables:

• •Longitudinal PSA kinetics under continuous ADT without compliance confounding
• •Time-to-CRPC emergence under defined androgen suppression depth (testosterone thresholds)
• •Comparative androgen pathway studies (intra-tumoral vs. systemic testosterone under medical castration)
• •Bone mineral density loss trajectory under chronic ADT (a clinically significant secondary endpoint)

---

Safety Profile and Research Considerations

Common adverse events (clinical trials):

• •Implant site reactions: mild bruising, pain, swelling (most common; typically resolve within 2 weeks)
• •Hot flashes / vasomotor symptoms (consequence of sex hormone suppression)
• •Headache, fatigue, mood changes (sex hormone deficiency effects)

Initial flare management: In prostate cancer patients, co-administration of an anti-androgen (bicalutamide, flutamide) for the first 2-4 weeks post-implant blunts the testosterone flare and its clinical consequences.

Bone mineral density: Prolonged sex hormone suppression (more than 6-12 months) is associated with accelerated bone resorption. In CPP treatment, this is generally offset by the reduced bone age advancement. In prostate cancer ADT, bone protection with bisphosphonates or denosumab is often co-prescribed.

Contraindications: Pregnancy, hypersensitivity to GnRH analogs, undiagnosed abnormal vaginal bleeding.

---

Key Research Resources

• •FDA Label — Supprelin LA: NDA 021-552
• •FDA Label — Vantas: NDA 021-287
• •Pivotal CPP trial: Eugster EA et al. Journal of Clinical Endocrinology and Metabolism, 2007
• •Prostate cancer ADT: Schlegel PN et al. Journal of Urology, 2006
• •GnRHR desensitization mechanism: Pawson AJ, McNeilly AS. Trends in Endocrinology and Metabolism, 2005

---

Summary

Histrelin's combination of potent GnRHR agonism and unique 12-month sustained-release implant technology makes it the most pharmacologically controlled long-duration GnRH agonist available. Its FDA-approved status, well-characterized safety profile, and reversible action position it as both a clinically validated therapeutic and a research tool for studying HPG axis biology, GnRHR receptor dynamics, pediatric puberty timing, and androgen deprivation oncology over extended timeframes.

For researchers working with GnRH agonist systems, histrelin's implant kinetics — flat zero-order release, no injection intervals, 12-month duration — eliminate confounding variables that complicate injectable GnRH agonist studies. Within the GnRH agonist family, it complements gonadorelin's acute stimulation utility and leuprolide's injectable depot paradigms, providing the sustained-suppression endpoint of the mechanistic spectrum.

---

This article is intended for researchers and healthcare professionals. Histrelin (Supprelin LA, Vantas) is an FDA-approved prescription medication available through licensed medical channels. All research applications must comply with applicable institutional, regulatory, and ethical guidelines.